Achaogen (NASDAQ:AKAO) appoints Ian Friedland, M.D., as its Chief Medical Officer. He joins the company from Cubist Pharmaceuticals (NASDAQ:CBST) where he was VP of Clinical Development. Dr. Friedland will be responsible for leading the Phase 3 clinical trial for plazomicin, the firm's lead product for serious bacterial infections due to MDR Enterobacteriaceae.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs